Literature DB >> 32512649

Preoperative frailty and outcome in patients undergoing radical cystectomy.

Ellen van der Vlies1,2, Maartje Los1, Pascal E F Stijns3, Marike van Hengel4, Nynke M S Blaauw1, Willem Jan W Bos1,2, Eric P A van Dongen5, Harm H E van Melick3, Peter G Noordzij5.   

Abstract

OBJECTIVE: To determine the value of preoperative frailty screening in predicting postoperative severe complications and 1-year mortality in patients undergoing radical cystectomy (RC). PATIENTS AND METHODS: Prospective cohort single-centre study in patients undergoing RC from September 2016 to December 2017. Preoperative frailty screening was implemented as standard care and was used to guide shared decision-making during multidisciplinary team meetings. Frailty screening consisted of validated tools to assess physical, mental and social frailty. Patients were considered frail when having two or more frailty characteristics. The primary endpoint was the composite of a severe complication (Clavien-Dindo Grade III-V) within 30 days and 1-year all-cause mortality. The secondary endpoints included any complication (Clavien-Dindo II-V), length of stay, readmission within 30 days, and all-cause mortality. Logistic regression analysis and the concordance statistic (c-statistic) were used to describe the association and predictive value of preoperative frailty screening.
RESULTS: A total of 63 patients were included; 39 (61.9%) were considered frail. Preoperative frailty was associated with a seven-fold increased risk of a severe complication or death 1 year after RC [adjusted odds ratio (OR) 7.36, 95% confidence interval (CI) 1.7-31.8; 22 patients]. Compared to the American Society of Anesthesiologists (ASA) score and Charlson Comorbidity Index, frailty showed the best model performance (Nagelkerke R2 0.20) and discriminative ability(c-statistic 0.72, P < 0.01) for the primary endpoint. After adding frailty to the conventional ASA risk score, the c-statistic improved by 11% (P < 0.01). Overall survival was significantly worse in frail patients (23.2 months, 95% CI 18.7-30.1) vs non-frail patients (32.9 months, 95% CI 30.0-35.9; P = 0.01).
CONCLUSIONS: Frail patients undergoing RC are at high risk of postoperative adverse outcomes including death. Preoperative frailty screening improves preoperative risk stratification and may be used to guide patient selection for RC.
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #BladderCancer; #blcsm; bladder carcinoma; frailty; radical cystectomy; risk assessment

Mesh:

Year:  2020        PMID: 32512649     DOI: 10.1111/bju.15132

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  The Association of Frailty with Outcomes after Cancer Surgery: A Systematic Review and Metaanalysis.

Authors:  Julia F Shaw; Dan Budiansky; Fayza Sharif; Daniel I McIsaac
Journal:  Ann Surg Oncol       Date:  2022-01-24       Impact factor: 5.344

2.  Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.

Authors:  Daan J Reesink; Ewoudt M W van de Garde; Paul van der Nat; Diederik M Somford; Maartje Los; Simon Horenblas; Harm H E van Melick
Journal:  World J Urol       Date:  2022-04-10       Impact factor: 4.226

3.  Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy.

Authors:  Allison S Letica-Kriegel; Amy L Tin; Garrett M Nash; Nicole E Benfante; Nita McNeil; Andrew J Vickers; Bernard Bochner; Sherri M Donat; Alvin Goh; Guido Dalbagni; Timothy Donahue; Eugene K Cha; Eugene Pietzak; Harry Herr; Beatriz Korc-Grodzicki; Armin Shahrokni
Journal:  Eur J Surg Oncol       Date:  2022-03-11       Impact factor: 4.037

4.  The CUSUM curve combined with comprehensive complication index for assessing short-term complications of radical cystectomy.

Authors:  Diansheng Zhou; Jie Gao; Yihao Liao; Jian Wang; Keke Wang; Jianqiang Zhu; Hailong Hu; Changli Wu; Dawei Tian
Journal:  J Clin Lab Anal       Date:  2022-07-26       Impact factor: 3.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.